早期经典霍奇金淋巴瘤中风险与获益的平衡
早期经典霍奇金淋巴瘤(HL)在定义明确的化疗和放疗(RT)及风险适应性治疗下,多数患者可治愈,当前主要目标是降低治疗相关毒性并维持长期疾病控制。本文综述了早期预后良好与预后不良患者的化疗联合IF/ISRT方案、2×BEACOPPescalated序贯2×ABVD与4×ABVD的比较、基于PET反应的策略以及PET指导省略RT的RAPID和H10试验结果,并提及维布妥昔单抗、纳武利尤单抗或帕博利珠单抗等药物可能进一步降低总体死亡率并改善生活质量。
要点
- 早期预后良好患者常用2×ABVD后20-Gy IF/ISRT,早期预后不良者常用4周期化疗后30-Gy IF/ISRT巩固。
- 与4×ABVD相比,2×BEACOPPescalated序贯2×ABVD改善5年PFS,5年OS相似。
- RAPID和H10试验均报告不放疗时疾病控制较差,但PET指导省略RT对RT相关毒性风险增高者可为有效选择。
核心结论
- 早期经典霍奇金淋巴瘤多数患者可治愈,当前主要目标是降低治疗相关毒性并维持长期疾病控制。
- PET指导省略放疗在放疗相关毒性风险增高的患者中可构成有效的治疗选择。
- 维布妥昔单抗、纳武利尤单抗或帕博利珠单抗等药物可能进一步降低总体死亡率并改善生活质量。
研究设计与样本
- 本文为综述,围绕早期经典霍奇金淋巴瘤风险与获益平衡的治疗策略进行汇总。
- 汇总内容包括定义明确的化疗和放疗、风险适应性治疗、PET反应指导策略及RAPID和H10试验。
- 检索范围原文未报告。
主要发现
- 早期预后良好患者(局限期无风险因素)常接受2×ABVD后20-Gy IF/ISRT。
- 早期预后不良患者(局限期有风险因素)通常接受4周期化疗后30-Gy IF/ISRT巩固。
- 与4×ABVD相比,2×BEACOPPescalated序贯2×ABVD改善5年PFS,5年OS相似。
- 早期预后不良患者中,多数在2×ABVD后中期PET阴性并于4×ABVD后结局良好;中期PET阳性者2×BEACOPPescalated改善5年PFS。
- RAPID和H10试验均报告不放疗时疾病控制较差,但PET指导省略RT对RT相关毒性风险增高者可为有效选择。
关键数值与推荐
- 早期预后良好:2×ABVD后20-Gy IF/ISRT。
- 早期预后不良:4周期化疗后30-Gy IF/ISRT巩固。
- 2×BEACOPPescalated序贯2×ABVD vs 4×ABVD:5年PFS改善,5年OS相似。
- 早期预后不良中期PET阳性者:2×BEACOPPescalated改善5年PFS。
- RAPID和H10试验:不放疗时疾病控制较差。
临床怎么用
- 早期预后良好患者可按2×ABVD后20-Gy IF/ISRT治疗。
- 早期预后不良患者可按4周期化疗后30-Gy IF/ISRT巩固治疗。
- 对RT相关毒性风险增高的患者,PET指导省略RT可构成有效的治疗选择。
- 维布妥昔单抗、纳武利尤单抗或帕博利珠单抗可能允许进一步降低总体死亡率并改善生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With defined chemotherapy and radiotherapy (RT) and risk-adapted treatment, early-stage classical Hodgkin lymphoma (HL) has become curable in a majority of patients. Hence, a major current goal is to reduce treatment-related toxicity while maintaining long-term disease control. Patients with early-stage favorable disease (ie, limited stage without risk factors [RFs]) are frequently treated with 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (2×ABVD) followed by 20-Gy involved-field or involved-site RT (IF/ISRT). In patients with early-stage unfavorable disease (ie, limited stage with RFs), 4 cycles of chemotherapy are usually consolidated with 30-Gy IF/ISRT. Compared with 4×ABVD, 2 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (2×BEACOPPescalated) followed by 2×ABVD improved 5-year progression-free survival (PFS), with similar 5-year overall survival. Recently, treatment strategies based on [18F]fluorodeoxyglucose positron emission tomography (PET) response were evaluated. In early-stage unfavorable HL, a majority of patients achieved a negative interim PET after 2×ABVD and an excellent outcome after 4×ABVD, whereas in those with a positive interim PET, 2×BEACOPPescalated improved 5-year PFS. Furthermore, a PET-guided RT approach was evaluated to decrease long-term toxicity. Although both the RAPID and H10 trials reported poorer disease control without RT, PET-guided omission of RT can constitute a valid therapeutic option in patients with an increased risk of RT-associated toxicity (eg, because of sex, age, or disease localization). Implementation of drugs such as the anti-CD30 antibody-drug conjugate brentuximab vedotin or the anti-programmed death 1 antibodies nivolumab or pembrolizumab might allow further reduction of overall mortality and improve quality of life in affected patients.
引用
- Bröckelmann PJ, Sasse S, Engert A, et al. Balancing risk and benefit in early-stage classical Hodgkin lymphoma. Blood. 2018. PMID: 29500174. doi:10.1182/blood-2017-10-772665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。